André Koch
Dresden University of Technology
66 Papers
281 Citations
André Koch is an academic researcher from Dresden University of Technology. The author has contributed to research in topics: Medicine & Skin cancer. The author has an hindex of 13, co-authored 64 publications.
Chat about Author
Papers
Cutaneous lymphomas in Germany: an analysis of the Central Cutaneous Lymphoma Registry of the German Society of Dermatology (DDG).
Chalid Assaf,Sylke Gellrich,Matthias Steinhoff,Dorothee Nashan,Dorothee Nashan,Franca Weiße,Edgar Dippel,Esther A. Coors,Esther A. Coors,Anette Stein,Philippa Gollin,Ulrike Henke,Sabrina Adam-Murati,André Koch,Claus-Detlev Klemke,Rudolf Stadler,Wolfram Sterry +16 more
TL;DR: Primary cutaneous lymphomas form a heterogenous group of lymphatic neoplasias that manifest themselves on the skin and are the second most frequent group of non‐Hodgkin lymphoma (NHL) following gastrointestinal lymphomas.
118
Acne inversa (Hidradenitis suppurativa): A review with a focus on pathogenesis and treatment
TL;DR: This new off-label drug treatment is particularly beneficial when used in combination with wide excision of inflamed skin and subcutaneous tissue and Retinoids have been reported to be helpful in secondary prevention.
50
Disabling pansclerotic morphea of childhood poses a high risk of chronic ulceration of the skin and squamous cell carcinoma.
Uwe Wollina,Michael Buslau,Birgit Heinig,Ivailo Petrov,Eleonore Unger,Eugenia Kyriopoulou,André Koch,Erich Köstler,Jaqueline Schönlebe,G Haroske,Thorsten Doede,Kyrill Pramatarov +11 more
TL;DR: A report on marked improvement of chronic leg ulcers by a combination of sildenafil 3 × 20 mg/day and repeated application of a porcine small intestinal submucosal acellular matrix.
46
Pityriasis rubra pilaris – a retrospective single center analysis over eight years
TL;DR: Pityriasis rubra pilaris is a rare papulosquamous dermatosis and co‐morbidities, complications, and outcome of treatment regimens are evaluated.
39
•Journal Article
Dissecting Cellulitis of the Scalp Responding to Intravenous Tumor Necrosis Factor-alpha Antagonist.
TL;DR: After introduction of anti-tumor necrosis factor-alpha treatment (infliximab), the malodorous discharge stopped, inflammation was reduced significantly, nodules became flat, and pain decreased.
32